David Raleigh, PhD, MD
UCSF
Radiation Oncology, Box 0520
1450 Third Street, Room 403
San Francisco, CA 94158
United States
Dr. David Raleigh is a radiation oncologist who specializes in brain tumors. He cares for both adult and pediatric patients.
Raleigh's research focuses on understanding the biological processes that cause brain tumors to grow. His goals are to uncover new measures of brain cancer and to identify cells for drugs to target.
Raleigh earned a bachelor's degree in molecular and cell biology as well as a bachelor's degree in cognitive science from the University of California, Berkeley. He earned his doctoral degree in molecular pathogenesis – how disease develops at the molecular level – from the University of Chicago, followed by his medical degree from the Pritzker School of Medicine at the University of Chicago. He completed a residency in radiation oncology at UCSF.
Raleigh is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, Pacific Pediatric Neuro-Oncology Consortium, Children's Oncology Group, Society for Neuro-Oncology, International Meningioma Society and North American Skull Base Society.
At the UCSF Brain Tumor Center, Raleigh is a principal investigator with the Wolfe Meningioma Program Project.
- Chen WC, Choudhury A, Youngblood MW, Polley MC, Lucas CG, Mirchia K, Maas SLN, Suwala AK, Won M, Bayley JC, Harmanci AS, Harmanci AO, Klisch TJ, Nguyen MP, Vasudevan HN, McCortney K, Yu TJ, Bhave V, Lam TC, Pu JK, Li LF, Leung GK, Chan JW, Perlow HK, Palmer JD, Haberler C, Berghoff AS, Preusser M, Nicolaides TP, Mawrin C, Agnihotri S, Resnick A, Rood BR, Chew J, Young JS, Boreta L, Braunstein SE, Schulte J, Butowski N, Santagata S, Spetzler D, Bush NAO, Villanueva-Meyer JE, Chandler JP, Solomon DA, Rogers CL, Pugh SL, Mehta MP, Sneed PK, Berger MS, Horbinski CM, McDermott MW, Perry A, Bi WL, Patel AJ, Sahm F, Magill ST, Raleigh DR. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 Nov 9. doi: 10.1038/s41591-023-02586-z. Epub ahead of print. PMID: 37944590.
- Perlow HK, Nalin AP, Handley D, Gokun Y, Blakaj DM, Beyer SJ, Thomas EM, Raval RR, Boulter D, Kleefisch C, Bovi J, Chen WC, Braunstein SE, Raleigh DR, Knisely JPS, Ivanidze J, Palmer JD. A Prospective Registry Study of 68Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial Meningiomas. Int J Radiat Oncol Biol Phys. 2023 Oct 21:S0360-3016(23)08020-3. doi: 10.1016/j.ijrobp.2023.10.014. Epub ahead of print. PMID: 37871886.
- Nejo T, Krishna S, Jimenez C, Yamamichi A, Young JS, Lakshmanachetty S, Chen T, Phyu SSS, Ogino H, Watchmaker P, Diebold D, Choudhury A, Daniel AGS, Raleigh DR, Hervey-Jumper SL, Okada H. Glioma-neuronal circuit remodeling induces regional immunosuppression. bioRxiv [Preprint]. 2023 Aug 6:2023.08.04.548295. doi: 10.1101/2023.08.04.548295. PMID: 37577659; PMCID: PMC10418167.
- Daggubati V, Vykunta A, Choudhury A, Qadeer Z, Mirchia K, Saulnier O, Zakimi N, Hines K, Paul M, Wang L, Jura N, Xu L, Reiter J, Taylor M, Weiss W, Raleigh D. Hedgehog target genes regulate lipid metabolism to drive basal cell carcinoma and medulloblastoma. Res Sq [Preprint]. 2023 Aug 3:rs.3.rs-3058335. doi: 10.21203/rs.3.rs-3058335/v1. PMID: 37577529; PMCID: PMC10418546.
- Vasudevan HN, Delley C, Chen WC, Mirchia K, Pan S, Shukla P, Aabedi AA, Nguyen MP, Morshed RA, Young JS, Boreta L, Fogh SE, Nakamura JL, Theodosopoulos PV, Phillips J, Hervey-Jumper SL, Daras M, Pike L, Aghi MK, Tsai K, Raleigh DR, Braunstein SE, Abate AR. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy. JAMA Netw Open. 2023 Aug 1;6(8):e2329186. doi: 10.1001/jamanetworkopen.2023.29186. PMID: 37589977; PMCID: PMC10436135.